Авторы

  • Gadaeva N.A.

Ключевые слова:

Klotho, кардиоренальный синдром, фактор роста фибробластов-23, сердце-почечное взаимодействие, хро- ническая болезнь почек, сердечная недостаточность.

Библиографические ссылки

1. Добронравов ВА. Современный взгляд на патофизио- логию вторичного гиперпаратиреоза: роль фактора роста фибробластов 23 и Klotho. Нефрология.2011;15(4):11-20.

2. Мухин НА, Моисеев ВС. Кардиоренальные соотно- шения и риск сердечно-сосудистых заболеваний. Вестн РАМН.2013;11:50-55.

3. Шутов АМ, Серов ВА. Кардиоренальный кон- тинуум или кардиоренальный синдром. Клин неф- рол.2017;1:44-48.

4. Bellasi A, Kooienga L, Block GA et al. How long is the war- ranty period for nil or low coronary artery calcium in patients new to hemodialysis? J Nephrol.2019;22:255-62.

5. Borst MH, Vervloet MG. Cross talk between the reninan- giotensinaldosterone system and vitamin D-FGF-23 klotho in Adragão T. A plain x-ray vascular calcification score is associ- ated with arterial stiffness and mortality in dialysis patients. Nephrol Dial Transplant.2009;24:997-1002.

6. Chung-YiC, Makoto K, Razzaque MS. Molecular regula- tion of phosphate metabolism by fibroblast growth factor 23 Klotho system.Adv. Chronic. Kidney Dis.2016;18(2):91-7.

7. Collins AJ, Foley RN, Chavers B. United States Renal Data System 2011 annual data report: atlas of chronic kidney dis- ease and end-stage renal disease in the United States. Amer J Kidney Dis.2017;59:1-420.

8. Devereux RB. The value of noninvasive measurements in hypertension. J Amer Med Assoc.2012;264(21):2798-2799.

9. Donate-Correa J, Mora-Fernández C, Martínez-Sanz R et al. Expression of FGF23/Klotho system in human vascular tis- sue. Int J Cardiol.2013;165(1):179-83.

10. Gadaev A, Ismoilova M, Turakulov R. Comparative analysis of calprotectin and helicobacter pylori in the faces and interleukin-6 in the blood of patients with and without COVID-19 before and after the treatment. Sci Coll «Inter- Conf+».2022;26(129):236-42.

11. Gadaev AG, Turakulov RI, Pirmatova NV, Hudjakulova FI. Evaluation the functional reserve of the kidneys in patients with chronic heart failure who have had the COVID-19 infec- tion.Нефрология.2022;263:59-65.

12. Goh CY, Ronco C. Cardio-Renal syndromes. J Renal. Care.2016;36:9-17.

13. Gosse P, Roudaut R, Dallocchio M. Is echocardiography an adequate method to evaluate left ventricular hypertrophy re- gression? Europ Heart J.2011;11(Suppl G):107-112.

14. Iwanaga Y, Miyazaki S. Heart failure, chronic kidney dis- ease, and biomarkers.Circ J.2016;6:52-8.

15. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int.2019;76(113):1-150.

16. London G.M. Left ventricular alterations and end-stage renal disease. Nephrol Dial Transplant.2020;17:29-36.

17. Maltese G, Karalliedde J. The putative role of the Phos- phorus and calcium in cardiovascular and renal disease.Int J Hypertens.2012;2012:757-69.

18. Mann D. Heart failure. Saunders.2014;25:36-47.

19. Milovanova L, Milovanov Y, Plotnikova A. Phosphorus and calcium metabolism disorders associated with chronic kidney disease stage III-IV (systematic review and meta-analysis). Chronic kidney disease and renal transplantation; Ed. by Man- isha Sahay. INTECH 2018:118-132.

20. Milovanova LYu, Milovanov YuS, Kozlovskaya LV. The place of paricalcitol in nephroprotective strategy of predialy- sis chronic kidney disease due to systemic diseases. Arh. Ev- romed.2014;3:69-78.

21. Mitani H, Ishizaka N, Aizawa T et al. In vivo Klotho gene transfer ameliorates angiotensin II-induced renal damage.Hy- pertension.2012;39(4):38-843.

22. Reslerova M, Moe SM. Vascular calcification in dialy- sis patients: Pathogenesis and consequences. Amer J Kidney Dis.2003;41:96-S99.

23. Wang Y., Sun Z. Klotho gene delivery prevents the pro- gression of spontaneous hypertension and renal damage. Hy- pertension.2019;54(4):810-7.